Loading...
XNAS
ENLV
Market cap29mUSD
Dec 05, Last price  
1.21USD
1D
4.31%
1Q
14.15%
Jan 2017
-76.73%
IPO
-82.46%
Name

Enlivex Therapeutics Ltd

Chart & Performance

D1W1MN
XNAS:ENLV chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.85%
Rev. gr., 5y
%
Revenues
0k
000000002,277,0000000
Net income
-15m
L-48.35%
-229,000-1,145,000-7,022,000-15,365,000-16,022,000-5,945,000-4,242,000-10,149,000-13,863,000-9,648,000-42,407,000-29,068,000-15,014,000
CFO
-13m
L-44.70%
-149,000-865,000-4,409,000-13,249,000-15,486,000-6,352,000-3,161,000-7,041,000-11,007,000-17,542,000-23,953,000-23,523,000-13,008,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
URL
https://www.enlivex.com/
IPO date
Jul 30, 2014
Employees
71
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT